Sydney, May 3, 2026, 23:02 AEST
CSL Limited bought back 110,004 shares on April 30 for A$13.69 million, a May 1 ASX filing showed, extending an on-market buyback as the Australian biotechnology group trades near multi-year lows. The filing showed CSL had already bought 6,242,085 shares before that day for A$1.044 billion; the company has said the program can reach up to US$750 million and run until June 30.
The timing is the point. CSL shares closed Friday at A$124.84, up 0.38%, but still barely above a 52-week low of A$123.88 and less than half the 52-week high of A$275.79, market data showed.
A buyback is one of the few immediate levers available to management while investors wait for cleaner earnings. In an on-market buyback, a company buys its own shares through the exchange; that can reduce the share count, but only helps sentiment if the core business steadies.
CSL’s half-year result set the backdrop. Revenue fell 4% to US$8.3 billion and reported net profit after tax dropped 81% to US$401 million on a constant-currency basis, which strips out exchange-rate moves; underlying NPATA, a profit measure excluding acquisition amortisation and major one-off items, fell 7% to US$1.9 billion. Chief Financial Officer Ken Lim said CSL was “clearly not satisfied” with the result, though the company kept fiscal 2026 guidance for 2% to 3% revenue growth and 4% to 7% NPATA growth, excluding restructuring and impairments.
The reset now sits with Gordon Naylor, the former CSL executive and non-executive director appointed interim chief executive and managing director from Feb. 11 after Paul McKenzie retired. Naylor said his “immediate priority” was to work with the board and leadership team on CSL’s strategic transformation.
The latest outside hit came from flu vaccines. Reuters reported last month that the U.S. military had scrapped its flu vaccine mandate, raising concern over demand from a key institutional buyer; Marc Jocum, senior product and investment strategist at GlobalXETFs, called it “incremental pressure at the worst possible time,” while Vantage Markets analyst Hebe Chen pointed to a “lack of clarity” around CSL’s forward strategy. CSL Seqirus generated about US$2.17 billion of revenue in fiscal 2025, or about 14% of the group total, Reuters reported. Reuters
That puts CSL’s vaccine arm in a tougher competitive frame. Sanofi, GSK and CSL Seqirus are among the leading makers in seasonal flu vaccines, and shifts in public-sector demand can matter quickly when immunisation rates are already weak.
But the downside is plain enough. A buyback can reduce the share count; it cannot by itself fix weaker U.S. immunisation rates or remove the execution risk in a restructuring that includes a planned Seqirus demerger, a net headcount cut of up to 15% and targeted annual pre-tax savings of US$500 million to US$550 million by fiscal 2028.
For now, CSL’s own ASX page shows a steady run of buyback updates, including May 1, April 30 and April 29. That gives investors a daily read on capital support. The harder read is whether Naylor can turn that support into a broader recovery in vaccines, plasma therapies and confidence before the buyback window closes.
